P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Leukemia and Lymphoma

• Publication date

  1995-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3109/10428199509056825PMID 8580789
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hemopoiesis.

  1994cited by this paper
• Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia.

  1994cited by this paper
• Apoptosis and cancer.

  1994cited by this paper
• Bcl-2 blocks p53-dependent apoptosis

  1994cited by this paper
• Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia.

  1994cited by this paper
• Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers

  1994cited by this paper
• BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax

  1994cited by this paper
• A cell cycle regulator potentially involved in genesis of many tumor types.

  1994cited by this paper
• Clinical implications of the p53 tumor-suppressor gene.

  1993cited by this paper
• p53 is required for radiation-induced apoptosis in mouse thymocytes

  1993cited by this paper
• bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia.

  1993cited by this paper
• Physical and functional interaction between WT1 and p53 proteins.

  1993cited by this paper
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

  1993cited by this paper
• p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy.

  1993cited by this paper
• bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia

  1993cited by this paper
• Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine.

  1993cited by this paper
• Aberrant Expression of the p53 Tumor Suppressor Gene in Adult T‐Cell Leukemia and HTLV‐I‐infected Cells

  1993cited by this paper
• p53: at the crossroads of molecular carcinogenesis and risk assessment.

  1993cited by this paper
• Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.

  1993cited by this paper
• Analysis of the p53 gene in patients with isochromosome 17q and Ph1-positive or -negative myeloid leukemia.

  1993cited by this paper
• p53 gene mutations and loss of a chromosome 17p in Philadelphia chromosome (Ph1)-positive acute leukemia.

  1993cited by this paper
• Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay.

  1993cited by this paper
• p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression

  1993cited by this paper
• The tumor suppressor p53 regulates its own transcription

  1993cited by this paper
• Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis.

  1993cited by this paper
• Sporadic mutations of the p53 gene in multiple myeloma and no evidence for germline mutations in three familial multiple myeloma pedigrees.

  1993cited by this paper
• p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy

  1993cited by this paper
• The importance of p53 gene alterations in human cancer: is there more than circumstantial evidence?

  1993cited by this paper
• p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.

  1993cited by this paper
• Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53

  1993cited by this paper
• Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine

  1993cited by this paper
• p53 mutations in B-cell chronic lymphocytic leukemia.

  1992cited by this paper
• Bcl-2 initiates a new category of oncogenes: regulators of cell death.

  1992cited by this paper
• Apoptotic cell death induced by c-myc is inhibited by bcl-2

  1992cited by this paper
• Regulation of the specific DNA binding function of p53.

  1992cited by this paper
• TP53 tumor suppressor gene: A model for investigating human mutagenesis

  1992cited by this paper
• Mutations of the p53 gene in human myeloma cell lines.

  1992cited by this paper
• The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors.

  1992cited by this paper
• Wild-type p53 binds to the TATA-binding protein and represses transcription.

  1992cited by this paper
• Apoptosis: final control point in cell biology.

  1992cited by this paper
• Constitutive expression of p53 protein in enriched normal human marrow blast cell populations.

  1992cited by this paper
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

  1992cited by this paper
• Absence of hereditary p53 mutations in 10 familial leukemia pedigrees.

  1992cited by this paper
• Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p.

  1992cited by this paper
• Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells.

  1992cited by this paper
• Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

  1992cited by this paper
• Mutations of p53 gene and their relation to disease progression in B-cell lymphoma.

  1992cited by this paper
• p53 function and dysfunction.

  1992cited by this paper
• Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases.

  1992cited by this paper
• Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations.

  1992cited by this paper
• Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis.

  1992cited by this paper
• Mutations of the p53 gene in adult T-cell leukemia.

  1992cited by this paper
• High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia.

  1992cited by this paper
• P53 gene mutations in acute myeloid leukemia with 17p monosomy.

  1991cited by this paper
• Analysis of multidrug resistance (MDR‐1) gene expression in chronic lymphocytic leukaemia (CLL)

  1991cited by this paper
• The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.

  1991cited by this paper
• Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis.

  1991cited by this paper
• Expression of the Multidrug Resistance Gene in Human Cancer

  1991cited by this paper
• The p53 tumour suppressor gene

  1991cited by this paper
• Adult T‐cell leukemia: Structures and expression of the p53 gene

  1991cited by this paper
• Levels of p53 protein increase with maturation in human hematopoietic cells.

  1991cited by this paper
• p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

  1991cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.

  1991cited by this paper
• Identification of p53 as a sequence-specific DNA-binding protein

  1991cited by this paper
• Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis

  1991cited by this paper
• Infrequent mutations in the P53 gene in primary human T-cell acute lymphoblastic leukemia.

  1991cited by this paper
• Mutation of the p53 gene in human acute myelogenous leukemia.

  1991cited by this paper
• p53 in chronic myelogenous leukemia in acute phase.

  1991cited by this paper
• Inactivation of the retinoblastoma gene in human lymphoid neoplasms.

  1991cited by this paper
• Genetic Alteration of p53 in Some Patients with Adult T‐Cell Leukemia

  1991cited by this paper
• Mutations of the p53 gene in lymphoid leukemia.

  1991cited by this paper
• Role of the human papillomaviruses in human cancer.

  1991cited by this paper
• p53 gene alterations in human hematological malignancies: a review.

  1991cited by this paper
• Mutations in the p53 gene in myelodysplastic syndromes.

  1991cited by this paper
• Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

  1990cited by this paper
• Expression of p53 protein during the cell cycle measured by flow cytometry in human leukemia.

  1990cited by this paper
• Different tumor-derived p53 mutants exhibit distinct biological activities.

  1990cited by this paper
• 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes.

  1990cited by this paper
• Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine.

  1990cited by this paper
• Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.

  1990cited by this paper
• Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

  1990cited by this paper
• Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides.

  1990cited by this paper
• Expression of Multidrug Resistance Gene in Human Cancers

  1989cited by this paper
• Expression of p53 in human leukemia and lymphoma.

  1986cited by this paper
• Growth regulation of a cellular tumour antigen, p53, in nontransformed cells

  1984cited by this paper
• Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes

  1984cited by this paper
• Participation of p53 cellular tumour antigen in transformation of normal embryonic cells

  1984cited by this paper
• Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation

  1984cited by this paper
• T antigen is bound to a host protein in SY40-transformed cells

  1979cited by this paper
• Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.

  1979cited by this paper

• Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells

  2023cites this paper
• Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL

  2019cites this paper
• Asrij/OCIAD1 suppresses CSN5-mediated p53 degradation and maintains mouse hematopoietic stem cell quiescence.

  2019cites this paper
• Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma

  2016cites this paper
• Translocation of the proto-oncogene Bcl-6 in human glioblastoma multiforme.

  2014cites this paper
• Animal Models of Burkitt’s Lymphoma

  2013cites this paper
• Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudin induces p53 signaling and apoptosis in HTLV-1-infected cells

  2013cites this paper
• A translational study on the roles of redox molecules, cell cycle regulators and chemokine receptors as prognostic factors in diffuse large B-cell lymphoma

  2013cites this paper
• Development and characterization of 5 canine B-cell lymphoma cell lines.

  2012cites this paper
• The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans.

  2012cites this paper
• The Role of PIDD in Apoptosis and Innate Antiviral Immunity

  2012cites this paper
• Hdm2 Small-Molecule Inhibitors For Therapeutic Intervention In B-Cell Lymphoma

  2012cites this paper
• Cytotoxic action of Ganoderma lucidum on interleukin‐3 dependent lymphoma DA‐1 cells: involvement of apoptosis proteins

  2011cites this paper
• Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas.

  2011cites this paper
• TP53 mutation and survival in chronic lymphocytic leukemia.

  2010cites this paper
• Epstein-Barr virus in Burkitt’s lymphoma: A role for latent membrane protein 2A

  2010cites this paper
• TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

  2010cites this paper
• Physiological and Pathological Role of Apoptosis

  2010cites this paper
• The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target

  2009cites this paper
• Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

  2009cites this paper
• Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis

  2009cites this paper
• Assessment of expression of selected Bcl-2 family proteins in lymphoid infiltration in patients with B-cell chronic lymphocytic leukaemia treated with nucleoside analogues.

  2008cites this paper
• Chromosomal Instability and Human T Cell Leukemia Virus 1 Transformation

  2008cites this paper
• Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway

  2008cites this paper
• Molecular Regulation of Apoptosis and Cell Cycle by Bcl-2 and FKBP38.

  2007cites this paper
• Inhibition of Methyltransferases Results in Induction of G2/M Checkpoint and Programmed Cell Death in Human T-Lymphotropic Virus Type 1-Transformed Cells

  2007cites this paper
• Detection of t(14;18), P53 and RAS gene mutations and quantification of residual disease in patients with B-cell non-Hodgkin's lymphoma.

  2007cites this paper
• An investigation into the cytotoxicity and mode of action of some novel N-alkyl-substituted isatins.

  2007cites this paper
• Lymphoproliferative clonal origin of AIDS-related non-Hodgkin's lymphoma

  2007cites this paper
• An investigation into the cytotoxic properties of isatin-derived compounds: potential for use in targeted cancer therapy

  2007cites this paper
• HICJ Hypermethylation Is a Late Event in Hematopoietic Neoplasmst

  2006cites this paper
• Analysis of p53 and Bak gene mutations in lymphoproliferative disorders developing in rheumatoid arthritis

  2006influential citation
• Radiation-induced caspase-8 mediates p53-independent apoptosis in glioma cells.

  2006cites this paper
• Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: mechanisms and clinical implications.

  2006cites this paper
• Involvement of Bax, Bcl-2 and caspase 3 in hydroxyurea- or etoposide-induced apoptosis of mouse interleukin-3-dependent lymphoma cells.

  2005cites this paper
• MUTATIONAL ANALYSIS OF p 53 IN 16 CASES OF ACUTE LYMPHOBLASTIC LEUKEMIA AND BURKITT ’ S LYMPHOMA

  2005cites this paper
• Repression of DNA Repair Mechanisms in IRF-4-Expressing and HTLV-I-Infected T Lymphocytes

  2005cites this paper
• Characterisation of TP 53 abnormalities in chronic lymphocytic leukaemia

  2004cites this paper
• Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia.

  2004cites this paper
• p53 regulates thymic Notch1 activation

  2004cites this paper
• The involvement of retroviruses in human T cell leukaemias and lymphomas

  2003cites this paper
• High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

  2003cites this paper
• Molecular pathology in the diagnosis and treatment of non‐Hodgkin's lymphomas

  2003cites this paper
• A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis

  2002cites this paper
• Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome).

  2002cites this paper
• The Molecular Basis of Human Cancer

  2002cites this paper
• The Molecular Biology of Leukemias

  2002cites this paper
• A Novel B-cell Line (U-2932) Established from a Patient with Diffuse Large B-cell Lymphoma Following Hodgkin Lymphoma

  2002cites this paper
• Targeted therapies for high-risk acute myeloid leukemia.

  2001cites this paper
• Apoptosis-Related Gene and Protein Expression in Human Lymphoma Xenografts (Raji) After Low Dose Rate Radiation Using 67Cu-2IT-BAT-Lym-1 Radioimmunotherapy

  2001cites this paper
• Anticancer drug resistance in primary human brain tumors.

  2001cites this paper
• Apoptosis Triggered by Myc-Induced Suppression of Bcl-XL or Bcl-2 Is Bypassed during Lymphomagenesis

  2001cites this paper
• p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.

  2001cites this paper
• mutation TP 53 as an alternative to ATM p 53 dysfunction in B-cell chronic lymphocytic leukemia : inactivation of

  2001cites this paper
• Apoptosis is critical for drug response in vivo.

  2001cites this paper
• The challenge of p53 as prognostic and predictive factor in Hodgkin's or non-Hodgkin's lymphoma

  2001cites this paper
• Recombinant fusion toxins directed against the human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor.

  2001cites this paper
• Evaluation of P53 in Relapsed and Refractory Aggressive NHL and Response to DHAP Protocol

  2000cites this paper
• Modulation of programmed cell death by medicinal plants.

  2000cites this paper
• Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in b‐cell non‐Hodgkin's lymphoma

  2000cites this paper
• c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells

  2000cites this paper
• p53 alterations in human leukemia–lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization?

  2000cites this paper
• BCL-6 in the Pathogenesis of Non-Hodgkin's Lymphoma

  2000cites this paper
• Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations.

  1999cites this paper
• Expression of p53 and retinoblastoma gene in high‐grade nodal peripheral T‐cell lymphomas: immunohistochemical and molecular findings suggesting different pathogenetic pathways and possible clinical implications

  1999cites this paper
• Original Articles c-MYC, RB-1, TP53, and Centromere 8 and 17 Copy Number in B-Cell Non-Hodgkin's Lymphomas Assessed by Dual-Color Fluorescence In Situ Hybridization

  1999cites this paper
• Implication of HTLV-I infection, strongyloidiasis, and P53 overexpression in the development, response to treatment, and evolution of non-Hodgkin's lymphomas in an endemic area (Martinique, French West Indies).

  1999cites this paper
• c-MYC, RB-1, TP53, and centromere 8 and 17 copy number in B-cell non-Hodgkin's lymphomas assessed by dual-color fluorescence in situ hybridization.

  1999cites this paper
• Mutational analysis of transgenic mouse B cell lymphomas: indication of a Trp53-independent pathway in tumor progression.

  1999cites this paper
• Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival

  1999cites this paper
• p53 gene deletion and trisomy 12 in hairy cell leukemia and its variant.

  1999cites this paper
• Overview of the role of molecular methods in the diagnosis of malignant lymphomas.

  1999cites this paper
• The usefulness of immunophenotypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasms. An update.

  1999cites this paper
• Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas.

  1999cites this paper
• Isochromosome 17 q in Blast Crisis of Chronic Myeloid Leukemia and in Other Hematologic Malignancies Is the Result of Clustered Breakpoints in 17 p 11 and Is Not Associated With Coding TP 53 Mutations

  1999cites this paper
• p53 mutation in a case of blastic transformation of follicular lymphoma with double bcl-2 rearrangement (MBR and VCR).

  1998cites this paper
• Induction of p53 by the concerted actions of aziridine and quinone moieties of diaziquone.

  1998cites this paper
• Inhibition of p53 Transactivation Function by the Human T-Cell Lymphotropic Virus Type 1 Tax Protein

  1998cites this paper
• Cell turnover parameters in small and large cell varieties of primary intestinal non‐hodgkin's lymphoma

  1998cites this paper
• Roles of the Tumor Suppressor p53 and the Cyclin-dependent Kinase Inhibitor p21WAF1/CIP1 in Receptor-mediated Apoptosis of WEHI 231 B Lymphoma Cells

  1998cites this paper
• Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression

  1998cites this paper
• Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications.

  1997cites this paper
• Mutational analysis of p53 in 16 cases of acute lymphoblastic leukemia and Burkitt's lymphoma.

  1997cites this paper
• Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization

  1997cites this paper
• Apoptosis: clinical relevance and pharmacological manipulation.

  1997cites this paper
• p53 abnormalities in B-cell prolymphocytic leukemia.

  1997cites this paper
• Phenolphthalein Induces Thymic Lymphomas Accompanied by Loss of the p53 Wild Type Allele in Heterozygous p53-Deficient (±) Mice

  1997cites this paper
• Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucine.

  1997cites this paper
• Functional and Physical Consequence of Human Immunodefficiency Virus Transactivator TAT Interaction with Human Cell Cycle Regulator p53

  1997cites this paper
• p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma.

  1997cites this paper
• p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy

  1997cites this paper
• Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.

  1997cites this paper
• Oncogenic changes in murine lymphoid tumors induced by in utero exposure to ionizing radiation.

  1997cites this paper
• HIC1 hypermethylation is a late event in hematopoietic neoplasms.

  1997cites this paper
• Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy.

  1997cites this paper
• p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis

  1997cites this paper
• Expression of Apo‐1/Fas (CD95), Bcl‐2, Bax and Bcl‐x in myeloma cell lines: relationship between responsiveness to anti‐Fas mab and p53 functional status

  1997cites this paper
• p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis.

  1996cites this paper
• Alterations of multiple tumor suppressor genes (p53 (17p13), p16INK4 (9p21), and DBM (13q14)) in B‐CELL chronic lymphocytic leukemia

  1995cites this paper
• N‐methylnitrosourea—lnduced Ki‐ras codon 12 mutations: Early events in mouse thymic lymphomas

  1995cites this paper